Your Source for BioScience Venture Capital Data
  • SEARCH THE OnBioVC DATABASE:

  • OnBioVC NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • Photobucket

  • FDA Registered Contract Manufacturer

Tangent Medical Technologies (Ann Arbor, MI) a development-stage medical device company focused on peripheral intravenous delivery systems, closed a $4.5M Series A financing. Participants include Arboretum Ventures, Flagship Ventures and Osage Ventures.

Agios Pharmaceuticals (Cambridge, MA) a clinical-stage biopharmaceutical company focused on cancer metabolism, closed a $78M Series C financing. Participants have included Celgene, ARCH Venture Partners, Flagship Ventures and Third Rock Ventures.

Acceleron Pharma (Cambridge, MA) is a clinical-stage biopharmaceutical company focused on protein therapeutics for anemia, cancer, Duchenne Muscular Dystrophy and bone loss diseases, closed a $30.4M Series D financing. Participants have included Advanced Technology Ventures, Avalon Ventures, Bessemer Venture Partners, Celgene, Flagship Ventures, MPM Capital, Orbimed, Polaris Ventures, QVT Financial, Sutter Hill Ventures and Venrock.

Averdo (Waltham, MA) a commercial-stage ophthalmology medical device company focused on procedures for biomechanically strengthening and modifying the cornea, closed on $25M Series C financing. Participants include SCP Vitalife, Aperture Venture Partners, Prism VentureWorks, De Novo Ventures, Flagship Ventures, Borealis Ventures and Echelon Ventures. Thanx for your patience as we catch-up.

Taris Biomedical (Lexington, MA) a clinical-stage specialty pharmaceutical company focused on bladder diseases in pain, inflammation, oncology and incontinence, closed a $18.3M Series B financing. Participants include Third Rock Ventures, Flagship Ventures, Flybridge Capital Partners and Polaris Venture Partners.

Accuri Cytometers (Ann Arbor, MI) a commercial-stage device company focused on flow cytometery solutions for the R&D market, closed a $6M Series E financing. Participants include Arboretum Ventures, Baird Venture Partners, Fidelity Biosciences, Flagship Ventures and InvestMichigan.

Visterra (Cambridge, MA) a development-stage company focused virus-glycan docking to derive products for the prevention, treatment and diagnosis of influenza and other infectious diseases, closed a $6M Series A financing. Participants include Flagship Ventures, Lux Capital and Polaris Venture Partners.

Joule Biotechnologies (Cambridge, MA) a development stage company focused on the conversion of carbon dioxide into ethanol, closed a $30M Series B financing. Participants include Flagship Ventures.

Tetraphase Pharmaceuticals (Watertown, MA) a clinical-stage biopharmaceutical company focused on broad spectrum antibiotics for the treatment of gram negative pathogens, unrinary tract infections and community acquired bacterial pneumonia, closed a $45M Series C financing. Participants include Excel Venture Management, CMEA Capital, Fidelity Biosciences, Flagship Ventures, Mediphase Venture Partners and Skyline Ventures.

T2 Biosystems (Cambridge, MA) a development-stage molecular and immunodiagnostic company focused on a nanotechnology and miniaturized magnetic resonance designed to optimize sample prep, closed a $12M Series C financing. Participants include Physic Ventures, Arcus Ventures, RA Capital, Camros Capital, WS Investments, Flagship Ventures, Polaris Venture Partners, Flybridge Capital Partners and Partners Healthcare.

Bind Biosciences (Cambridge, MA) a preclinical-stage biopharmaceutical company focused on differential medicinal nanoengineered delivery of targeted therapeutics and controlled drug exposure to diseased tissue for various cancers, closed an $11M Series C financing. Participants have included DHK Investments, ARCH Venture Partners, Flagship Ventures, NanoDimension and Polaris Venture Partners.

TransMedics (Andover, MA) a clinical-stage medical device company focused on a technology platform to maintain donor organs in near-physiologic and functioning condition during transport for organ transplantation, closed a $36M Series E financing. Participants include Foundation Capital, Kleiner Perkins Caufield & Byers, Flagship Ventures, 3i Group, Tudor Investment, VantagePoint Venture Partners, Sherbrooke Partners, Alta Partners, [...]

Eleven Biotherapeutics (Cambridge, MA) a preclinical-stage biopharmaceutical company focused on protein therapeutics for the treatment of inflammation and coagulation disorders, closed a $35M Series A financing. Participants include Flagship Ventures and Third Rock Ventures. _________________________________________________________________________ NOTE: New OnBioVC Friday feature coming, well…this Friday!

« Previous Entries  Next Page »

to top of page...